首页 | 本学科首页   官方微博 | 高级检索  
     


Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial
Authors:Irene Terrenato PhD  Francesca Sperati PhD  Felice Musicco PharmD  Anna F. Pozzi PharmD  Annunziata di Turi PhD  Mauro Caterino MD  Elisabetta de Lutio di Castelguidone MD  Sergio V. Setola MD  Massimo Bellomi MD  Carlo E. Neumaier MD  Laura Conti MD  Giovanni Cigliana PhD  Roberta Merola PhD  Anna Antenucci PhD  Giulia Orlandi PhD  Antonio Giordano MD PhD  Maddalena Barba MD PhD  Stefano Canitano MD
Affiliation:1. Biostatistic Unit, Regina Elena National Cancer Institute, Rome, Italy;2. Service of Pharmacovigilance, Regina Elena National Cancer Institute, Rome, Italy;3. AUSL di Bologna, Bologna, Italy;4. Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy;5. Department of Diagnostic Imaging, Regina Elena National Cancer Institute, Rome, Italy;6. Department of Diagnostic Imaging, Radiant and Metabolic Therapy, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy;7. Department of Medical Imaging and Radiation Sciences, European Institute of Oncology, Milan, Italy;8. Department of Oncology and Hematology‐Oncology, University of Milan, Milan, Italy;9. Diagnostic Imaging and Senology, IRCCS‐A.O.U., San Martino‐IST, Genoa, Italy;10. Departement of Clinical Patology, Regina Elena National Cancer Institute, Rome, Italy;11. Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscano Tumori (ITT), Siena, Italy;12. Department of Biology, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, Pennsylvania;13. Division of Medical Oncology 2, Regina Elena National Cancer Institute, Rome, Italy
Abstract:
Keywords:cancer patients  contrast induced nephropathy  low‐osmolar/iso‐osmolar contrast medium
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号